BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
Growing
The company is in a growing phase, with the latest annual income totaling USD 8.99M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 8.99M.
Fairly Valued
The company’s latest PE is -3.76, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 28.69M shares, decreasing 9.72% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 193.51K shares of this stock.